Wikisage, the free encyclopedia of the second generation, is digital heritage

Rufinamide

From Wikisage
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Lennox-Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconclusive. Otsuka et al. (2014) state rufinamide as an efficacious and well tolerated AED [1](cf. Alssad et Coren 2014) [2]

"Rufinamide received the status of orphan drug for epilepsy in 2004 in Europe" [3]

It is an inductor of CYP 450

Weblinks

FLexikon:Rufinamid

Pharmawiki:Rufinamid

ATC

https://www.whocc.no/atc_ddd_index/?code=N03AF03

References

References:
  1. ↑ Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan
  2. ↑ Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials
  3. ↑ Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience

Q408565 at Wikidata  Interwiki via Wikidata

Retrieved from "http://en.wikisage.org/w/index.php?title=Rufinamide&oldid=11317"